New COVID-19 Treatment available at WHMS

West Holt Medical Services is among area medical providers who received an allotment of investigational monoclonal antibodies which received an emergency use authorization (EUA) from the FDA for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. The treatment is administered intravenously.

Per the FDA, these monoclonal antibodies are authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.

Monoclonal antibodies are not authorized for use on patients who have been hospitalized due to COVID-19 and not everyone who tests positive for COVID-19 may meet the criteria to receive the treatment. If you have tested positive for COVD-19 and believe you may qualify, please reach out to your primary care provider (PCP).

Even if you do not qualify for monoclonal antibody treatment, contacting your PCP when you test positive for COVID-19 may help you and your family take more effective steps to ensure your health and safety as they may be more familiar with your specific history and situation.